In an interview with Targeted Oncology, C. Ola Langren, MD, discussed the continuing impact of the groundbreaking FDA ODAC ...

In the evolving landscape of haematologic cancers, the concept of minimal residual disease, also known as measurable residual ...

In the last year, there has been excitement about the use of MRD in multiple myeloma trials and new approaches to assessing ...

A healthy Sri Lankan woman who thought she injured herself doing household chores says her true diagnosis shocked everyone. Diagnosed with multiple myeloma, Sharn Hegan is now cancer-free, but there ...

Janssen, the pharmaceutical arm of Johnson & Johnson and a leader in healthcare, has announced the launch of Tecvayli in the ...

An innovative blood cancer treatment regime could extend remission by seven months on average, according to a clinical trial ...